A new preclinical model using CRISPR, an advanced technology that allows scientists to cut and edit genes, has given Weill Cornell Medicine researchers and their colleagues a deeper insight into how ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

CRISPR Therapeutics is commercially validated with CASGEVY but remains financially unproven and operates at a loss. Click to read this CRSP stock update.

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...

Scientists at the University of Glasgow developed a bioengineered bone marrow (BM) model that helped them to evaluate potential use of a combined CRISPR-CAR T cell therapy in the treatment of acute ...

Scientists from Mass General Brigham and the Broad Institute of MIT and Harvard have used CRISPR screens to identify genetic modifications that influence T cell function and survival in cultures and ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

This session presents two linked talks on CRISPR–Cas9 model generation and sequence validation. Christopher Raymond will discuss how direct zygote editing in mice and rats reduces timelines and costs ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...